Graft-versus-Host Disease (GVHD)
Graft-versus-host disease (GVHD) is one of the most serious multisystem immune complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT) or, less often, solid organ transplantation. At its core, GVHD is an alloimmune reaction: immunocompetent T lymphocytes from the graft (the donor) recognize the human leukocyte antigens (HLA) or minor histocompatibility antigens of the host (the recipient) as foreign. They then launch a chain of cytotoxic and systemic inflammatory responses that attack the host's tissues.
Of the main target organs (skin, liver, gut and lungs), the skin is affected earliest and most often. It is involved in more than 80% of patients with acute GVHD and in most cases of chronic GVHD. Skin findings range from mild, itchy papular red rashes and scaling to widespread epidermal necrosis resembling toxic epidermal necrolysis (TEN/Lyell syndrome) in acute GVHD, or lichenoid lesions and scleroderma-like hardening that can deform the skin and contract the joints in chronic GVHD.
At Haute-Derma, managing skin GVHD brings together careful differential diagnosis (ruling out drug reactions such as DRESS/TEN and post-transplant viral rashes), non-invasive assessment with high-frequency ultrasound (HFUS) and dermoscopy, and intensive skin-directed treatment: NB-UVB/PUVA phototherapy, fractional ablative laser, topical immunosuppressants and barrier repair. The goals are to ease itching, prevent tissue fibrosis and improve quality of life after transplant.
Pathogenesis and Main Clinical Forms
Skin GVHD develops through three successive immune phases:
- Phase 1 (initial tissue damage): Myeloablative conditioning or chemotherapy before the transplant damages the host's endothelium and epidermis, releasing inflammatory cytokines (TNF-α, IL-1, IL-6) and activating antigen-presenting cells (APCs).
- Phase 2 (donor T-cell activation): Donor T cells interact with host APCs, multiply and differentiate into cytotoxic (CD8+) and helper (CD4+) T cells.
- Phase 3 (target organ cytotoxicity): Activated T cells home to the skin and kill keratinocytes through perforin/granzyme B, Fas/FasL signaling and TNF-α (keratinocyte apoptosis), while also altering the collagen structure of the dermis.
Main Clinical Forms in the Skin
Acute Cutaneous GVHD (aGVHD)
- Onset: Usually within the first 100 days after transplant (or later in late-onset aGVHD).
- Appearance: A red maculopapular rash that typically starts on the palms, soles, ears, face and neck, then spreads to the trunk and limbs.
- Severity staging (Glucksberg / NIH criteria):
- Stage 1: Rash on < 25% of body surface area (BSA).
- Stage 2: Rash on 25–50% BSA.
- Stage 3: Rash on > 50% BSA (generalized).
- Stage 4: Generalized erythroderma with blisters, pustules or widespread epidermal sloughing (TEN/Lyell-like).
Chronic Cutaneous GVHD (cGVHD)
- Onset: Usually more than 100 days after transplant; it may follow aGVHD or arise on its own.
- Lichenoid cGVHD: Flat, slightly scaly violet-brown papules resembling lichen planus, with nail destruction on the fingers or toes and lacy, Wickham-like changes in the mouth.
- Sclerotic cGVHD: Thick, hard, rough skin that loses its elasticity and becomes bound down to the tissues beneath, with mottled pigmentation (poikiloderma) and a serious loss of joint movement.
Clinical Classification of Skin GVHD
| Clinical Form | Typical Onset | Characteristic Features |
|---|---|---|
| Mild to moderate aGVHD (grade I–II) | Within the first 100 days | Papular red rash on palms, soles and face; mild to moderate itch |
| Severe aGVHD (grade III–IV) | Within the first 100 days | Generalized redness, blisters, TEN-like skin sloughing |
| Lichenoid cGVHD | After 100 days | Flat violet lichen-like papules, nail and mucosal involvement |
| Sclerotic cGVHD | After 100 days | Hard, bound-down skin, reduced joint movement, dermal fibrosis |
Our Evidence-Based Diagnostic Process at Haute-Derma
- Detailed history and examination: We review the transplant timeline, the conditioning regimen and all current medications (to rule out drug allergy), and grade the body surface area involved (BSA).
- Dermoscopy and high-frequency ultrasound (HFUS, 22–50 MHz):
- Dermoscopy: Shows linear vascular patterns, loss of sweat pores and pinpoint areas of epidermal necrosis.
- HFUS: Measures dermal and subcutaneous thickness, showing superficial edema in aGVHD or dense, echogenic bands of fibrosis in sclerotic cGVHD.
- Skin biopsy (histopathology):
- aGVHD: Vacuolar change of the basal layer and satellite cell necrosis (Civatte bodies), with dying keratinocytes next to cytotoxic T cells.
- cGVHD: Dense fibrosis of collagen bundles in the deep dermis, epidermal atrophy and T-lymphocyte infiltrates around blood vessels.
- Immune assessment and ruling out infection: Blood counts, calcineurin inhibitor (tacrolimus/cyclosporine) levels, and bacterial and viral swabs (HSV, CMV, VZV) from affected skin.
Treatment and Interventions at Haute-Derma
Alongside the systemic immunosuppression prescribed by the hematology and transplant team, Haute-Derma provides layered skin-directed treatment to protect the skin, control symptoms and tackle fibrosis:
Barrier Repair and Local Control of Inflammation
- Topical immunosuppressants: A potent corticosteroid (clobetasol propionate 0.05%) or a calcineurin inhibitor (tacrolimus 0.1% or pimecrolimus 1%), applied 1–2 times a day to bring flares under control.
- Protecting the lipid barrier: A moisturizer with ceramides, cholesterol and free fatty acids in a physiologic ratio helps rebuild a skin barrier damaged by immune attack.
Phototherapy
- Narrowband UVB (311 nm) / 308 nm excimer laser: Used for lichenoid cGVHD or aGVHD that responds poorly to topical treatment. UVB triggers apoptosis of T cells infiltrating the skin and suppresses Langerhans cells.
- UVA1 (340–400 nm) / PUVA: The preferred option for sclerotic cGVHD. UVA1 reaches deep into the dermis and prompts fibroblasts to release matrix metalloproteinases (MMP-1), which break down excess collagen and soften fibrotic tissue.
Procedures and Restoring Range of Motion
- Fractional CO2 laser: For sclerotic bands that limit movement, fractional CO2 laser creates microscopic treatment zones of thermal injury that trigger collagen remodeling and soften contracted skin.
- Wound care and biologic dressings: Hydrogel dressings or regenerative biologic membranes are applied to peeling or eroded skin to prevent secondary infection.
